Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DWJ1589 and DWC202315 in Healthy Volunteers
NCT06592495Phase 1Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Serum Concentration and Area Under the Curve to the Last Measurable Concentration. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06592495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592495.